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1. Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which attacks the joints but
also  may cause  extra-articular  complications.  The  disease  can  present  itself  in  a  variety
of ways. It  depends on many factors,  including the presence of rheumatoid factor,  pres‐
ence and rate  of  anti-CCP,  number of  swollen and painful  joints  (over  20 in the begin‐
ning  of  the  disease),  levels  of  inflammatory  markers  (ESR,  CRP),  patient’s  young  age,
occurrence  of  rheumatoid  nodules.  Patients  who  present  the  above  criteria,  especially
with  early,  polyarticular  onset  of  the  disease,  have  usually  aggressive,  progressive  and
destructive course of the disease manifested by extra-articular manifestations. Proper pri‐
mary treatment  in  the early  stage of  RA may reduce the number of  swollen joints  and
severity  of  inflammation,  slow  the  progression  of  joint  deformations  and  decrease  the
amount  of  erosions.  However,  it  does  not  completely  preserve  the  occurrence  of  extra-
articular  complications.  A  lot  of  these  complications  can  be  observed  in  patients  with
long lasting  RA,  with  recurrent  exacerbations,  undertreated or  non compliant.  Many of
RA symptoms can also be seen in other diseases. That is why the recognition of the dis‐
ease in many times is difficult.
In this paper we provide overview of major extra-articular complications of RA, describing
its incidence and clinical features. To illustrate the complexity, variety of course and most
common diagnostic problems, descriptions of four case studies are also included.
© 2013 Romanowska-Próchnicka et al.; licensee InTech. This is an open access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
2. Non joint related complications of rheumatoid arthritis
Because there is no agreed classification of complications accompanying RA, this paper in‐
cludes not only extra articular manifestations but also non-articular complications of RA.
2.1. Rheumatoid anemia
Normocytic or microcytic anemia is a relatively common feature of RA. The development of
anemia is related to the effects of proinflammatory cytokines: tumor necrosis factor alpha
(TNF-α), interferon gamma (IFN-γ), interleukin-1 (IL-1), and interleukin-6 (IL-6) [1].
Anemia in RA is a result of iron deficiency, related to increased hepcidin production, which
is a recognized key factor of this disease. Hepcidin is a peptide hormone produced by the
liver. It inhibits intestinal iron absorption, iron release from macrophages and hepatocytes
and placental iron transport [2]. As a result, these mechanisms decrease iron delivery. The
main mediator of hepcidin increase in inflammation is IL-6 [2]. The IL-6–dependent STAT-3
pathway and the unfolded protein response–associated cyclic AMP response element-bind‐
ing protein-H (CREBH) pathway are responsible for the signal transduction pathways that
regulate hepcidin during inflammation and endoplastic reticulum stress [3].
Another factor regulating hepcidin level during inflammation is IL-1. It has been shown that
hepatocytes can be stimulated directly by the cytokines IL-6, IL-1α, and IL-1β to produce
hepcidin [4]. Moreover, IL-1 induces hypoferremia [5], up-regulates ferritin [6], and plays a
primary role in the anemia of chronic inflammation [7].
It has been shown that increased TNF–α levels correlate with systemic iron deficiency [8].
Levels of TNF-α were found to be significantly higher in anemic compared to non-anemic
patients [9]. TNF–α is a pro-inflammatory cytokine that decreases iron level through mecha‐
nisms that are independent of the induction of hepcidin [10]. Experiments with laboratory
animals shown that treatment with TNF-α down-regulate mucosal transfer of iron [11]. Du‐
odenal ferritin levels are induced in these animals, providing for iron storage during the
acute phase response [12]. This mechanism would prevent dietary iron exsorption across the
mucosa to circulation [13]. Treatment of macrophages with TNF-α, surprisingly is associat‐
ed with a rise in intracellular free or labile iron that is required for activation of the tran‐
scription factor NF-κB [14]. NF-κB is an important regulator of cellular responses to stimuli
such as stress. Reduction of intracellular iron by chelation has an inhibitory effect on NF-κB
induction of TNF-α and other cytokines [15,16]. Further studies of the TNF-α mechanism are
needed to better understand its reciprocal relationship with iron and control of the NF-κB
inflammatory response [13].
It is considered that IFN-γ can also modulate iron status. Recent In vitro studies suggest that
IFN-γ may modulate hepcidin induction by M. tuberculosis infected macrophages [17]. In
vivo studies have shown that a high iron diet will reduce IFN-γ [18], implicating its role in
the deleterious effects that iron-loading can have on the immune response. IFN-γ is a key
modulator of macrophage iron status and immune functions [13]. In vitro studies show that
IFN-γ could induce nitric oxide production–mediated apoptosis process, which might be in‐
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volved in the pathogenesis of anemia in RA patients [19]. There is evidence suggesting that
increased local IFN- γ production in bone marrow may be implicated in the pathogenesis of
anemia seen in up to 50% of patients with RA [20].
The best way of correcting anemia is to control systemic disease by treatment with disease-
modifying antirheumatic drugs (DMARDs). It has been shown that treatment with inflixi‐
mab and methotrexate significantly improves hemoglobin level among anemic RA patients
when compared to treatment with placebo and methotrexate [21]. In trials of tocilizumab in
RA substantial increase of hemoglobin levels was shown in patients with anemia in compar‐
ison to patients without the disease [22]. In patients with persistent anemia, an erythropoie‐
tin therapy may be considered. Erythropoietin therapy might be used if hormone level in
serum is lower than 500 mU/ml [23].
2.2. Rheumatoid nodules
Rheumatoid nodules (RN) are the most common extraskeletal manifestations of RA. RN oc‐
cur in approximately 20-35% of seropositive patients [24]. It does not depend on the severity
of inflammation. Rheumatoid nodules usually appear in patient with long lasting and active
inflammation process in RA (average disease duration of eleven years) [33]. However, 11%
of patients have RN in early stage of the disease, sometimes even earlier than inflammation
process in the joints. RN affects males more than females. Nodules are formed most fre‐
quently in soft tissues, skin colored, painless, movable. However, they can also be painful
and attached to the structure below tendons and bursae. They gain size from 2 mm to a cou‐
ple of centimeters in diameter. They appear in extensor parts of limbs in the proximal area
of interphalangeal and metacarpophalangeal joints, proximal forearm, elbows, foots and an‐
kles [25]. The nodules can occur not only subcutaneous but also internally – in lungs [26]
and other internal organs (heart [27], liver [28], pancreas [29], kidney [30]).
In histopathology, rheumatoid nodules contain massive areas of sharply defined necrobiosis,
specifically eosinophilic necrobiotic granuloma in the centere, surrounded by a palisade of
macrophages and fibroblasts, and a peripheral vascular area containing T lymphocytes and
macrophages. Nodules have collagen degeneration and common fibrosis. Usually there are
inflammatory components (tuberculoid and sarcoid reactions) [31]. Immunohistochemical
studies of a rheumatoid nodules (RN) suggest that it is a Th1 granuloma with focal vasculi‐
tis. According to Hodkinson, patients with rheumatoid nodules have increased level of cir‐
culating Th1 and IL-12, IL-2, and VEGF levels and IL-8, than those without RN [32].
Etiology of RN is unknown, but there are series of studies suggesting that nodules are an
effect of repeated trauma in the local tissue, which induce local vascular damage, and in‐
crease the level of proangiogenesis factors and cause granulation of tissue formations [32].
Nodules are usually asymptomatic but sometimes there is inflammation, ulceration, deeper
nodules can have fistula. In this case a surgical and antibiotic treatment is required. Al‐
though RNs are a cosmetic issue and usually do not need medical treatment. Nodules can
enlarge, recur or persist indefinitely. Sometimes nodules undergo remission after colchicine,
hydroxychloroquine and D-penicillamine [34]. There are two (Ching et al. and Baan et al.)
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double-blind randomized studies with corticosteroids injections and placebo [35,36]. Ching
et al. injected 24 nodules in 11 patients and concluded that it is a safe and effective way of
treating rheumatoid nodules [36]. Baan et al. has a similar conclusion. Surgical removal of
the nodules may be considered if they limit joint motion [35].
2.3. Thrombocytosis
Thrombocytosis  is  one of  the  most  common extra-articular  manifestations  of  RA and is
often correlated with the disease activity. Thrombocytosis is a manifestation observed in
40% of active patients with rheumatoid arthritis, it usually occurs during the active clini‐
cal stages of RA.
Thrombocytes or platelets are cytoplasmic fragments shed from mature megakaryocytes.
These cells are implicated in the pathophysiology of a number of connective tissue disor‐
ders, including RA. Presence of platelets was documented in synovium [37] and synovial
fluid of RA patients [38]. Activation of platelets in RA was observed in number of studies
[39-42]. Platelet alpha granules contains number of biologically active substances, which re‐
leased in response to activation, may contribute to the inflammatory cascade. Thrombocytes
are a source of a number of substances e.g. P-selectin, platelet-derived growth factor, CTAP-
III, acidic and basic fibroblast growth factor, epidermal growth factor, transforming growth
factor beta, which may influence inflammation [43]. Positive correlation between P-selectine,
platelets number and RA activity was observed [39].
Recent studies indicate that proinflammatory cytokines, playing a role in disease develop‐
ment, may have also megakaryocytopoetic/thrombopoetic properties [43]. Persistent over‐
production of certain thrombocytopoietic factors can induce megakaryocytopoiesis and
thrombocytopoiesis [44]. The megakaryocytopoiesis and inflammatory cascade of RA share
hematopoietic cytokines and respond to a number of colony-stimulating factors. Progenitors
of osteoclasts are important cells during the development of erosion [45]. Megakaryocyto‐
poiesis – is a complex process of development of megakaryocytes from pluripotent stem
cells. The process includes a number of events: cell division, endoreplication, abortive mito‐
sis, and maturation which may result in the biogenesis of platelets [43]. Megakaryocytes and
platelet production are dependent on the interactions of hematopoietic stem/progenitor
cells, the bone marrow stromal microenvironment and intracellular events and are influ‐
enced by certain interleukins, colony-stimulating factors (CSF), and hormones which stimu‐
late proliferation and differentiation at different stages [46]. Each day, approximately two
hundred milliards of platelets are released into the circulation of healthy adults [43].
The  main  proinflammatory  cytokines  of  RA,  TNF-α  and  IL-1β,  could  contribute  to  the
production  of  thrombocytes.  Although  not  primarily  involved  in  the  production  of
thrombocytes in the marrow, TNF-α and IL-1 can influence on thrombocytosis during in‐
flammation  by  inducing  synthesis  and  secretion  of  megakaryocytopoietic  cytokines  (i.e.
stem cell factor, granulocyte colony-stimulating factor, IL-6, IL-11, and leukemia inhibito‐
ry factor) [rewieved by 43]. Interleukin-1 is also a potent inducer of IL-6 megakaryopoie‐
sis stimulatory cytokine [47].
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IL-4 important anti inflammatory cytokine may also play dual regulatory role in thrombo‐
poiesis of RA. It functions as a downregulator of megakaryocytopoiesis [48], but also inter‐
acts with other cytokines, costimulating the growth of hematopoietic precursors [49-51]. It
was shown that IL-4 increases along with IL-1 and IL-6 in patients with active RA complicat‐
ed by thrombocytosis [43, 52 and 53].
Roles of different pleiotropic megakaryocytopoietic cytokines have been investigated in pa‐
tients with thrombocytosis secondary to RA. Among those cytokines, IL-6 predominates in
the stimulation of megakaryopoiesis [54]. Moreover, IL-6 may be responsible for the higher
TPO in inflammatory events [55]. IL-6 and thrombopoietin (TPO) may be responsible for the
development of reactive thrombocytosis in RA [52, 53 and 56]. Thrombopoietin (TPO) is the
main regulator hormone of platelet production. The binding of TPO to its receptor influen‐
ces all stages of megakaryocyte development and thrombocytosis both in vivo and in vitro
[57]. Enhanced megakaryocyte and platelet mass can act as negative feedback to the mega‐
karyocytopoiesis via receptor-mediated uptake and catabolism of the TPO [57]. Therefore,
TPO, proinflammatory cytokines, anti-inflammatory mediators, megakaryocyte mass, and
platelets themselves act in concert to regulate megakaryocytopoiesis of RA. Platelets can al‐
so be activated, and the growth hormones secreted from their alpha granules may actively
contribute to the tissue inflammation associated with RA [39-42].
2.4. Pulmonary involvement
Pulmonary involvement includes pleurisy/ pleural effusion, rheumatoid nodules, interstitial
involvement, pulmonary vasculitis - pulmonary hypertension, airways involvement (oblit‐
erative bronchiolitis), drug-induced lung diseases.
Patients with RA have different prevalence of lung involvement. Estimated prevalence de‐
pends on the method of detection. For example, the incidence of lung involvement based on
X-rays occurs in 1-12% of patients [58]. Next the functional test of lung capacity reveals
5-15% prevalence of restrictive lung disease [59]. However a reduction in the capacity of the
lung to diffuse carbon monoxide was observed in more than 50% of the patients with RA
[60]. The high-resolution computer tomography (HRCT) is the most sensitive detector of
pulmonary changes in RA patients. The prevalence of lung involvement is up to 80% in RA
patients [60].
Pleurisy/pleural effusion are the most common manifestations of the lung disease in RA.
The prevalence is about 5- 20% of patients with rheumatoid arthritis [61]. The occurrence is
significantly higher when considering postmortem studies - 40% - 75% [62]. Pleurisy ap‐
pears in patients with active RA, more frequently in males than females. The amount of
pleural effusion is usually small, and most of the patients do not require pleural puncture.
The fluid is present over a couple of weeks. It resolves usually after corticosteroids therapy
and DMARD’s therapy. Sometimes when the amount of the fluid is high and the patient has
symptoms of pulmonary insufficiency (short of breath, chest pain, cough) the thoracentesis
is needed. Each time any infections and malignancy should be excluded in the first place.
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Pulmonary rheumatoid nodules are usually coexisting with subcutaneous rheumatoid nod‐
ules and occur in patients with positive rheumatoid factor. Prevalence is different. It de‐
pends on a radiological method. Rheumatoid nodules are detected by X-ray in 0,2% of RA
[63] patients and in 4% by HRCT [64]. Males are affected more often than females. Pulmona‐
ry nodules can be single or multiple, usually are asymptomatic. They appear in periphery
right middle lobe or both upper lobes, gain from a couple of millimeters to a couple of centi‐
meters in diameter [65]. In most cases a patient requires biopsy and malignancy exclusion.
In histological examinations the pulmonary nodules look similar to the subcutaneous nod‐
ules. They are characterized by a central zone of fibrinoid necrosis, surrounded by a layer of
palisading mononuclear cells within an outer zone of vascular granulation tissue, lympho‐
cytes, plasma cells, and fibroblasts [66, 67].
In 1953 Caplan [68] described coexistence of rheumatoid nodules and pneumoconiosis in
chest radiographs of coal miners suffering from RA. X-rays show that the nodules are about
0.5 centimeter up to a couple of centimeters in diameter, and also a massive fibrosis. Nod‐
ules can collapse or calcify [68]. The course of the disease is sudden, it can regress or prog‐
ress. It develops especially in miners working in anthracite coal-mines and in people
exposed to silica and asbestos [69]. Prevalence is higher among patients with silicosis. In Ca‐
plan’s syndrome, a hypergammaglobilinemia with high level of alpha 2- globulin and a hi‐
poalbuminemia may occur [70]. Unge et al. investigated thirteen cases of Caplan's syndrome
by chest X-ray, rheumatic and immunological tests, heart and lung physiology and patho‐
logical-anatomical specimens. No positive correlation was found between exposure time to
silica, radiological findings and the level of rheumatoid factor. There was also no correlation
found between the degree of rheumatic inflammations and pulmonary progress. The hy‐
pothesis that silica acts as an adjuvant was not reflected in rheumatic parameters [71]. Pa‐
tients with Caplan’s syndrome require DMARD’s therapy. In case of a progression in the
lungs, the corticosteroid therapy is needed.
Interstitial  lung  disease  is  one  of  the  lung  manifestations  in  RA patients.  According  to
the recent American Thoracic Society (ATS)/European Respiratory Society consensus clas‐
sification, idiopathic interstitial  pneumonias (IIPs) include seven clinico-radiologic-patho‐
logic entities:
• idiopathic pulmonary fibrosis (IPF),
• usual interstitial pneumonia (UIP),
• nonspecific interstitial pneumonia (NSIP),
• cryptogenic organizing pneumonia,
• acute interstitial pneumonia,
• respiratory bronchiolitis-associated ILD,
• desquamative interstitial pneumonia,
• lymphoid interstitial pneumonia[72]
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Hyun-Kyung Lee et al. performed a retrospective study at Asian Medical Center to investi‐
gate the histopathologic patterns of interstitial lung diseases in patients with RA and their
correlation with clinical features and outcome [73]. UIP was the most common (55.6% in
10/18 patients) of the lung involvement in RA patients. NSIP was second popular (33.3% in
6/18). UIP was determine as fibrosis (fibrotic lesion and honeycombing). NSIP was divided
in 3 histopatholgic subgroups. First group was distinguished with interstitial inflammation,
second group, with both inflammations, and fibrosis, and third group, primarily with fibro‐
sis. The UIP group had worse diagnosis than the NCIS group [73].
Clinical features of pulmonary fibrosis in RA patients are similar to those of idiopathic pul‐
monary fibrosis. 90% of pulmonary fibrosis patients have earlier joints diseases. Males with
seropositive RA are more exposed than females [74]. Patients with pulmonary fibrosis in RA
reveal both lymphocytic alveolitis and neutrophilic inflammation with or without pulmona‐
ry fibrosis in bronchoalveolar lavage (BAL). This study showed increased levels of CD4 and
CD4:CD8 ratio in lymphocytic alveolitis [75].
The pathogensis of pulmonary fibrosis depends on two types of factors – RA-independent
and RA-associated. The RA independent factors are linked with tobacco usage and alpha-1
antitrypsin level. The RA-associated factors combine with genetical predisposition of HLA
gene occurrence and the cytokines level, especially proinflammatory cytokines by alveolar
macrophages, in particular TNF-α [76].
Patients with pulmonary fibrosis have a different course of the disease. Some cases have a
slowly progressing disease, some have stable course, while others show a rapidly deteriorat‐
ing process of the disease. Severe loss of pulmonary functions is rare [77].
Drug induced pulmonary involvement in patients with RA can occur after methotrexate
therapy, gold salts, D-pecicilammine, sufasalzine.
Methotrexate – pneumtonitis (MTX pneumonitis) is not a common complication but a life-
treating one. The data about the prevalence of MTX pneumonitis in RA shows a great varia‐
tion. Several retrospective and prospective studies have reported prevalence rates between
0.3% and 11.6% [78]. The methotrexate complications can occur with a dose of 7.5 mg per
week, as early as 1 month after initiation of therapy, and as late as two years therapy [79].
The clinical presentation of methotrexate – pneumonitis is nonspecific. In general, patients
have a nonproductive cough, dyspnoe, fever, pleuric chest pain. Physical examination often
reveals bilateral inspiratory crackles. Laboratory findings may include mild leukocytosis or
eosinophilia. The X-rays could be normal or could reveal interstitial lung diseases. The high
resolution tomography (HRCT) reveals “ground glass”. The pathology of the methotrexate -
pneumonitis is unknown. However a toxic drug reaction is suggested by the accumulation
of methotrexate in lung tissue. Age, sex, cumulative or weekly dose of methotrexate and the
disease duration, are not associated with the development of MTX-pneumonitis. Recent
studies suggest 5 conditions that induce an increased risk of the development of MTX- com‐
plication: diabetes mellitus, hypoalbuminemia, rheumatoid pleuropulmonary involvement,
previous use of disease-modifying agents (gold, sulfasalazine, or penicillamine), older age
[79]. Patients who are suspected of MTX-induced lung toxicity should cancel methotrexate
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therapy. Most of the patients improve without any other intervention, but in some cases the
corticosteridotherapy is needed.
The treatment of interstitial fibrosis in RA is variable because of variable course of pulmona‐
ry involvement. Generally, high daily doses of steroids are beneficial in some patients. In
some cases immunosuppressive (azathioprine or cyclophosphamid) agent should be added
to steroid therapy. Raghu et al. reported a prospective double-blind, randomized, placebo-
controlled clinical trial with azathioprine combined with prednisone in the treatment of idi‐
opathic pulmonary fibrosis. This study shows the efficacy of azathioprine associated with
prednisone and both the frequency and risk of side effects are lower than those of cyclo‐
phosphamide [80].
2.5. Amyloidosis
Secondary amyloidosis is potentially a life treatening complication of RA. The prevalence
estimates from 7% to 26% in RA patients [81]. Amyloidosis is worldwide and prevalence de‐
pends on demographic location. For example, a study from Finland of the autopsy records
of 1666 patients with RA revealed a prevalence of amyloidosis of 5.8% [82]. SAA1 gene poly‐
morphism increases frequency of amyloidosis. The frequency of SAA1 genotype is higher
among Japanese, Chinese, and white Australians than in other races. The frequency of SAA1
in Japanese is about 40% [83].
Amyloidosis is characterized by extracellular tissue deposition of fibrils that are composed
of fragments of serum amyloid A (SAA) protein produced by hepatocytes. Secondary amy‐
loidosis occurs during chronic inflammations. In developing countries secondary amyloido‐
sis coexist with chronic, infectious diseases, tuberculosis, leprosy, bronchiectasis, chronic
osteomyelitis, and chronic pyelonephritis. In industrialized countries, noninfectious diseases
such as rheumatoid arthritis (23-51%), juvenile idiopathic arthritis (7-48%) and ankylosing
spondylitis (0-12%) may cause amyloidosis [84, 85]. It occurs in patients with RA, who have
long and very active aggressive course of disease. Amyloidosis is related to the acute phase
of inflammation and elevated serum SAA1 level. SAA synthesis and secretion by hepato‐
cytes is mediated by cytokines, mainly IL-1, TNF-α and IL-6 [86].
The diagnosis of secondary amyloidosis is based on histological examination of tissue from
fat tissue, upper gastro intestinal duct or rectum. The most common presentation in amyloid
is renal. Renal involvement in RA patient with amyloidosis is approximately 90% of all. Al‐
most every patient with renal involvement has proteinuria. In some cases a renal insufficien‐
cy (high level of creatynina and low level of GFR) may appear. Amyloidosis is associated
with the occurrence of nephrotic syndrome (proteinuria> 3.5 g, hypoalbuminaemia, vascular
edema of lower limb). The amyloid can be present in spleen and liver. However, even severe
damage of liver and spleen is usually asymptomatic. Heart involvement occurs in 10% pa‐
tients with RA. This is shown as poor diagnostic factor.
Survival rate of patients diagnosed with amyloidosis in RA is approximately 4-5 years [87].
The clinical risk factors associated with a poor survival are: female gender, older age, re‐
duced serum albumin, and increased serum creatinine concentration [88].
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First aim in treatment of amyloidosis in RA is to decrease the level of serum amyloid A,
by  means  of  inflammation  processes  suppression.  The  effective  DMARD’s  therapy  and
biologic  therapy  can  cause  decreased  level  of  inflammation  and  reduce  probability  of
amyloidosis. First drug therapy in amyloidosis is based on immunosupresive agents (cy‐
clophosphamide [89], methotrexate [90], and azathioprine [91]), which improve the prog‐
nosis.  According  to  Nakamura  et  al.  cyclophosphamide  therapy  is  more  effective  than
methotrexate therapy in secondary amyloidosis in RA patients [92]. Biologic agents (anty
TNF-α therapy) and inhibitor IL-6 decrease the level of serum Amyloid A by decreasing
the polymorphism SAA1 gene. T. Nakamura performed a study about efficacy of etaner‐
cept in patients with AA amyloidosis secondary to rheumatoid arthritis.  The conclusion
of this study is that etanercept is safe and effective even in patient on hemodialysis [93].
The latest Nakamura study proved that etanercept treatment was more effective than cy‐
clophsphamide treatment  [94].  Eprodisate  is  a  new class  of  antiamyloid compounds for
treating AA amyloidosis, which results in a significant delay in progression to hemodial‐
ysis or end-stage renal disease in AA amyloidosis [95].
2.6. Sjögren's syndrome
Sjögren’s syndrome (SS) is a chronic autoimmune inflammatory disease that affects lacrimal
and salivary glands causing mucous dryness [96]. The symptoms are related to diminished lac‐
rimal and salivary gland function and frequently present with keratoconjunctivitis sicca, xerop‐
thalmia, xerostomia, sialadenitis, cervical caries and infections. SS can cause also systemic
manifestations. They are subdivided into nonvisceral (skin, arthralgia, myalgia) and visceral
(lung, heart, kidney, gastrointestinal, endocrine, central and peripheral nervous system).
Sjögren’s syndrome is called secondary SS (sSS) when it is associated with other autoim‐
mune disorders such as scleroderma and RA [97]. Sjögren's syndrome definition was devel‐
oped by the team of experts from Europe and America, "European American consensus
group criteria" (EACG) that requires for recognition criteria:
• Subcjective ocular symtoms: symptoms of dry eyes over 3 months, forgein body sensation
in the eyes,
• Subjective oral symtoms: symtoms of dry mouth over 3 months, swollen salivary glands
• Objcective ocular signs: Abnormal Schirmer Test ( tears flow less then 5 mm in 5 minutes)
• Objective oral signs: unstimulated whole salivary flow less then 1.5 ml in 15 minutes, ab‐
normal parotid sialography, abnormal salivary scintigraphy
• Positive histopathological examination of lymphocytic infiltration at salivary glands, at
least one focus score,
• Positive antibody titers antiSSA/SSB.
The SS diagnosis requires a presence of one subcjective symptom plus 2 of the 3 objective
criteria [98].
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The development of SS secondary to RA occurs on a different genetic background (HLA
DR4). A distinct set of therapeutic responses suggest different pathogenetic processes [99,
100]. SS secondary to RA seems to be a complication of this disorder: the sicca syndrome is
less serious, Ab to Ro/SSA and La/SSB are present less frequently and the evolution of SS is
closely linked to that of RA. SS secondary to RA usually is subclinical and requires specific
tests for its diagnosis [99, 101].
As the physiopathology of these two diseases is distinctive, it is possible to suggest that pa‐
tients with RA and secondary SS have two different diseases [96]. In primary SS there is an
important role of B cells and type I interferon [97,102] in contrast to the predominance of
Th17 cytokines in RA [103]. It was suggested that decreased expression of TGF-α1 observed
in patients with SS secondary to RA might promote joint destruction [101]. The concentra‐
tion of TGF-α1 was significantly higher in patients with RA than in those with SS accompa‐
nying RA and in control group. The highest serum TGF-α1 concentrations were found in
patients with most severe joint damage, as evidenced by Steinbrocker stage. TGF-α1 is cyto‐
kine that prevents inappropriate autoimmune responses [101].
The exact prevalence of sSS in RA varies considerably, depending on the definition of sSS,
disease duration of RA and geographic region [102]. It has been demonstrated in Spain that
patients with RA duration up to 10 years have had a prevalence of secondary SS of 17% and
after 30 years it was as high as 25% [103]. Another study of early arthritis in the UK con‐
firmed the dependence of the prevalence of sSS on disease duration [104], but this relation‐
ship was not confirmed in the study from Norway [105]. However, significant correlation
was found between reduced salivary production and RA disease activity [105]. Geographi‐
cal variation was shown in a comparative study between Greek and British RA patients, sSS
was demonstrated in 43% and 17%, respectively [106]. The prevalence of sSS may reflect
geographical factors, but could also be due to the range of anti-TNF therapy [101].
The high prevalence of dry eyes in RA patients without fulfilling the diagnostic criteria for
secondary SS has been noticed by Fujita et al. [107] who found it in 90% of non-SS RA pa‐
tients. In his study only 10% of patients had Secondary SS. The correlation between secon‐
dary SS and disease activity was also studied. It was found that RA activity had no
significant correlation with the presence of dry eyes. However there was some correlation to
patients diagnosed with secondary SS [106]. Antero et al. could not find a higher RA activity
measured by DAS-28 in patients with secondary SS when compared to the ones without it
during the studies of Brazilian population. Neither secondary SS occurrence, nor eye sicca
subjective and objective findings have any relation to the disease duration [101]. The pres‐
ence of sicca symptoms was high in the studied population, although only 24% of patients
met the criteria of secondary SS [101]. Ocular symptoms of dryness were more common
than oral ones in RA patients [101]. The impact of sSS on RA is illustrated by a twofold in‐
creased risk of non-Hodgin’s lymphoma compared to RA patients without sSS [108], and
there is a tendency of increased mortality in RA patients with sSS compared to RA patients
without sSS [109,110].
A therapy for the Secondary Sjögren’s syndrome with RA can be divided into four separate
aeras. First is to manage the dryness in the eyes and mouth as well as the skin and other
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mucosal surface. Next is to treat non-visceral manifestations such as arthralgia and myalgia,
chronic fatigue syndrome. These symptoms are generally treated with salicylates, nonsteroi‐
dal agents, and hydroxychloroquine [111]. Patients with SS have a low tolerance of NSAIDs
resulting from dysphagia, secondary to decreased saliva flow and increased frequency of
gastro-oesophageal reflux disease. Usually patients with RA and SS use low doses of ste‐
roids and hydroxychloroquine to reduce arthaligia and myalgia. For visceral involvement,
including vasculitic skin lesions, pneumonitis, neuropathy, and nephritis, corticosteroids are
used with the dosage of 0.5 mg per one kilogram body mass. Drugs such as hydroxychloro‐
quine, azathioprine, and methotrexate are used to help the corticosteroids [112]. Methotrex‐
ate seems to be more useful than azathioprine in Seconadry Sjögren’s syndrome with RA
[113]. The biological agent used in SS is rituximab. The recent studies show a significant de‐
crease in fatigue, however no significant changes in secondary endpoints assessing glandu‐
lar manifestations (unstimulated salivary flow rate and Shirmer's test results) [114, 115]. For
life-threatening complications the cyclophosphamide therapy is needed. Lymphocytic ag‐
gressive manifestations, including lymphoma in SS with RA, require interdisciplinary help -
hematologists.
2.7. Vasculitis
Rheumatoid vasculitis is a rare but most serious systemic complication of rheumatoid arthri‐
tis. It typically affects small and medium-size vessels. It occurs almost exclusively in patients
with seropositive nodular RA who suffer from RA for at least 10 years and is associated
with poor prognosis [116-118]. 40% of patients die within 5 years as well as significant mor‐
tality due to both organ damage from vasculities and consequences of the treatment
[119-121]. Althought diagnostic criteria for systemic rheumatoid vasculitis were originally
described in 1984 by Scott et al. [122], no validated definition of vasculities exist. Recent
studies suggest that rheumatoid factor, anti-cyclic citrullinated polypeptide (CCP) positivi‐
ty, male gender, tobacco use, rheumatoid nodules, and older onset or long disease duration
confer added risk of vasculities [116]. Patients with the Felty`s syndrome are also prone to
vasculitis [121].
There appears to be a genetic predisposition toward developing rheumatoid vasculitis. RA
studies focused mainly on the third hypervariable region of HLA-DRB1 called the shared
epitope. Recent studies suggest a relationship between rheumatoid vasculitis and three spe‐
cific genotypes of the HLA-DRB1 shared epitope: *0401/*0401, *0401/*0404, and *0101/*0401
[118]. Research performed by the Mayo Clinic described a new correlation of HLA-C3 with
rheumatoid vasculitis [123]. Strong correlation of smoking with the development of rheuma‐
toid vasculitis was also discovered [123]. Other studies have also supported this relation, not
only in rheumatoid vasculitis but also in other extra-articular manifestations [124]. Higher
levels of anti-cyclic citrullinated polypeptide (CCP) antibodies levels were observed in pa‐
tients with RA, who have systemic vasculities [125]. The presence of anti-CCP antibodies in
patients with RA is linked to a progressive joint damage and severe extra-articular manifes‐
tations [121, 125]. During the studies of evaluating anti-CCP and RA vasculitis, antibodies
were detected in 93% of patients with systemic RA vasculitis and only in 7% of patients with
Extraskeletal Manifestations in Rheumatoid Arthritis – Clinical Cases
http://dx.doi.org/10.5772/53739
141
primary systemic small vessel vasculitis [121, 125]. However many patients with RA who
have circulating or tissue-deposited immune complexes and high levels of autoantibodies
do not develop vasculitis [124]. Systemic inflammation accompanying the development of
RA promotes early and aggressive atherosclerotic vascular disease which may present simi‐
lar to vasculitis manifestations. In such case, histopathologic confirmation of vasculitis is re‐
quired [124]. Characteristic histopathology confirmation of vasculitis is generally necessary
for a diagnosis of rheumatoid vasculitis. Other clinical and laboratory features are often sup‐
portive and may be used to assist a follow-up [124].
Pathologic features of rheumatoid vasculitis include mononuclear cells or neutrophilic infil‐
tration of the vessel wall of small and medium vessels. Features of vessel wall destruction
are often found, including necrosis, leukocytoclasis, and disruption of the internal and exter‐
nal elastic lamina. An important observation is that inflammation of more than three cell
layers of the vessel is a significant feature to distinguish rheumatoid vasculitis from RA
without vasculitis [124,126]. RA vasculitis may involve a number of body organs. Manifesta‐
tions differ depending on involved part of the body. The most common sites of involvement
are the skin and peripheral nerves. Cutaneous manifestations of rheumatoid vasculitis in‐
clude palpable purpura, focal digital lesions, nodules, ulcers, digital necrosis and pyoderma.
Peripheral nervous system involvement may be represented by distal sensory or motor neu‐
ropathy, mononeuritis multiplex. Central nervous system involvement may result in transi‐
ent ischemic attack, stroke, or seizure. Vasculitis development in the eye manifestates in
corneal ulceration and scleromalacia. Pulmonary involvement includes fibrosing alveolitis
and alveolar hemorrhage. Vasculitis in major organs is much less common but can lead to
significant morbidity and mortality, including myocardial infarction, bowel ischemia, and
renal failure [124].
High incidence of cardiovascular-related deaths is observed in patients with RA. Dawson et
al. noted that 31 % of the RA patients had an estimated pulmonary artery systolic pressure
of 30 mmHg or more, and 21% of all the RA patients had pulmonary hypertension [127]. Se‐
vere pulmonary hypertension in patients with RA is not common and usually is associated
with other collagen-vascular diseases such as progressive systemic sclerosis, syndrome of
calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly and telangiecta‐
sia [128]. Pulmonary hypertension might be considered as primary or secondary. Primary
pulmonary hypertension is often clinically silent until well advanced. It has a very poor
prognosis and a median survival of only 2–3 years [129]. Secondary pulmonary hyperten‐
sion progresses slower than the primary form. Treatment of pulmonary hypertension initial‐
ly needs to be directed at the underlying cause. In RA, the pulmonary hypertension is
usually a result of RA-associated lung disease and implies a poor prognosis.
A number of structural abnormalities have been reported in RA patients population. Aortic
root enlargement, pericardial effusion, mitral valve abnormalities and impaired left ventric‐
ular function are more common in patients with RA than in control groups [127]. It has been
noted that RA patients have an increased number of abnormalities related to the function of
the left ventricle [130]. Impairment of left ventricular function may cause elevation of pres‐
sure on the left atrium which results in raises of the pulmonary artery pressure. Mild to
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moderate primary pulmonary hypertension is a common case in the RA population. Daw‐
son et al. identified that 31% of hospital RA patients have pulmonary hypertension on echo‐
cardiography. In these patients no significant symptoms, signs, ECG or structural
echocardiographic changes were apparent, probably because of early stage of disease [127].
Shortness of breath as a result of cartiorespiratory disesase in RA may appear because of
constraints arising from RA. It was suggested that number of deaths that have been previ‐
ously linked to ischaemic heart disease, may really have had been due to primary pulmona‐
ry hypertension [127].
A treatment of vasculitis depends on the degree of organ system involvement. Mild rheuma‐
toid  vasculitis  involving  the  skin  or  peripheral  nerves  can  be  treated  with  prednisone
(30-200mg/day) and methotrexate (10-25 mg/week) or azathioprine (50-150 mg/day). More seri‐
ous organ system involvement may require treatment with higher-dose steroids and cyclophos‐
phamide or biologic agents [124]. Management of patients with RA vasculitis should take into
account the increased risk of comorbidities in particular from cardiovascular disease [121].
2.8. Pericarditis and myocarditis
Pericarditis is one of the most common extraskeletal manifestations in RA. It occurs in
30-50% of the patients [131]. The highest occurrence of the disease is observed in male pa‐
tients with destructive and nodular RA [132]. It occurs seldom, require echocardiographic
diagnostics which may show asymptomatic pericardial involvement. Symptoms can also in‐
clude chest pains and pericardial effusion. Prognosis of RA patients with pericarditis de‐
pends on age, cardiac status. The prognosis is best when diagnosed in the first year [133].
Majority of patients develop pericarditis after arthritis begins, however pericarditis may also
manifest before diagnosis of RA. Early diagnosis of RA is then relevant, and effective treat‐
ment improves the outcome of patients with RA [134]. Treatment with non-steroidal anti-
inflammatory drugs, corticosteroids and/or other immunosuppressive drugs seems
appropriate in the majority of patients with a definite diagnosis of RA-associated pericardi‐
tis, and in severe cases, pericardiectomy is required [135].
Patients with RA have a two to five times increased risk of developing severe and prema‐
ture cardiocascular disease [136]. Relationship between cardiocascular risk and inflamma‐
tion has been suggested. Endothelial dysfunction, reduced arterial elasticy and
compressibility and increased atherosclerotic burden observed in RA support this theory
[137-139]. Diffused necrotizing or granulomatous myocarditis may be a cause of cardiomy‐
opathy. Postmortem histological studies showed cardiomyopathy in 3-30% of RA parients
[131]. Pathogenesis includes myocyte injury, local and systemic cytokine-mediated immune
responses, cell activation with cellular infiltration, oedema and necrosis [130]. It was hy‐
pothesized that elevated proinflammatory cytokines such as TNF-α, IL-1, IL-6 observed in
RA may be associated with concomitant myocardial tissue injury [141]. These mechanisms
occur to involve simultaneous activation of collagenolytic enzymes, MMPs [142]. Increased
T2-ER observed in RA patients reflects ongoing inflammatory injury and persistence of tis‐
sue oedema in RA myocardium [141].




These cases are included to illustrate the complexity, variety of course, complications and
most common diagnostical problems with the rheumatoid arthritis.
3.1. Case nr. 1
A 26 years old female with 14 years history of seropositive rheumatoid arthritis. She has very ag‐
gressive course of disease. While diagnosed rheumatoid arthritis she had elevated rheumatoid
factor – 1030 IU/ml, highly positive level of anti-citrullinated protein/peptide antibodies (AC‐
PA) – 1137 U/ml, elevated level of inflammations factors - CRP, ESR. Furthermore she had objec‐
tive factors of inflammations in the joints - overgrowth of synovium and infiltrations in joints
cavity detected in ultrasound. The aggressive course of the disease correlates with progress in
radiological changes in the joints. Radiogram of the hands shows Fourth Degree in Larsen Scale
- it means that in the joints space there are severe erosions, with no joint space left and the origi‐
nal bone outlines are partly presented [143]. Radiograms of the legs show Second Degree in
Larsen Scale - it means that in the joints space there are only one or several small erosions and di‐
ameter of the joints space is more than 1mm [143]. Therefore the patient required many surgi‐
cal procedures. She underwent linear osteotomy of metatarsal bones of right foot in 2007 and
had stabilizations of the left and right wrist with reconstruction of extensor palmaris of the sec‐
ond and third finger in the left hand in 2007. Then she received endoprosthesis of MCP II-III
bones of the right hand in 2010. .
Physical examination showed symetric polyarthritis involving arms, wrists, metacarpopha‐
langeal joints, proximal interphalangeal joints, knees, ankles and feet, 18- tender joints, 12–
swollen joints, morning stiffness >120min, Disease Activity Score 28 (DAS28)- 6,67
She was treated with a variety of disease modifying antirheumatic drugs (DMARD’s) over the
years –sulfasalazine - in 2003 - 2007, chloroquine – in 2003-2007, cyclosporine – in 02.2009-
04.2009 - with not good clinical response. After that she was treated with methotrexate. At first
she was taking 7,5 mg i.m/week between 13.06.2007 - 18.09.2007. She showed intolerance to the
drug – leucopenia. Next trial with methotrexate was in 17.03.2008 – 16.09.2008. She was treated
with the dose of 10 mg -15 per os. She presented intolerance to the drug again- high level of liv‐
er enzymes, nausea. Methotrexate therapy was discontinued definitely. Next she received leflu‐
nomide – 20 mg/day from 04.02.2009 to 06.04.2009, also showing bad tolerance - leucopenia,
high level of liver enzymes. After the DMARD’s therapy failed, she was treated with anti TNF-α
- etanercept 50mg sc/week for almost 2 years. In the end the patient did not show enough clini‐
cal response (difference between courses DAS28 < 1,2) and the therapy was canceled. Then she
took tocilizumab - 480mg i.v./month – monotherapy - 6 courses, good response. Her Disease Ac‐
tivity Score 28 (DAS28) went near remission 2,98.
This case shows the patient in early age with very aggressive course of disease. She had high
level of rheumatoid factor and anti-CCP antibody. She developed high level of radiological
changes in joints and required surgical procedures. Her other risk factor of aggressive rheu‐
matoid arthritis is poor response to disease modifying antirheumatic drugs and anti TNF-α.
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This is a classical example of patient who has statistically high level of risk factor to develop
destructive course of rheumatoid arthritis.
The most important thing in diagnostic process is to recognize a patient with high risk of
aggressive course of the disease. Next the patient should receive appropriate treatment that
includes combined therapy of at least two different DMARD’s (disease modifying antirheu‐
matic drugs ) and in case of ineffectiveness of this therapy – also biologic agents. In case of
seropositive RA with methotrexate intolerance patient should receive anti-TNF-α therapy in
monotherapy (etanercept or adalibumab). If this therapy is not successful patient should be
receiving inhibitor IL-6 – tocilizumab or fusion protein bind CTLA-4 - abatacept. This treat‐
ment can slow down or even stop the progression of the disease [144].
 
Figure 1. Case nr.1. A 26-year old woman with 14 years of rheumatoid arthritis. She underwent linear osteotomy of
metatarsal bones of right foot in 2007 and had stabilizations of the left and right wrist with reconstruction of extensor
palmaris of the second and third finger in the left hand in 2007. Then she received endoprosthesis of MCP II-III bones
of the right hand in 2010.
Radiological changes are the visual outcome of the progressive rheumatoid arthritis. Thus,
developed erosions in the joints in early stage of the disease prove joints destruction and
probability of functional disability. There are predictive factors of long-term radiographic
outcomes in early rheumatoid arthritis. N. Courvoisier performed a long-term study of 10
years to investigate predictive factors of radiographic outcome in RA and found the best in‐
dependent predictive factor of the 10-year radiographic score to be baseline erosion score
[145]. According to N. Courvoisier high level of erythrocyte sedimentation rate (ESR), pres‐
ence and level of IgA rheumatoid factor, presence of an anti-citrullinated protein antibody
(ACPA), serum level of matrix metalloproteinase-3 and radiographic score at baseline are
the most important factors to predict which patients will develop severe form of rheumatoid
arthritis. Interesting conclusion from this research work was that several demographic and
clinical parameters, such as sex, age and number of tender or swollen joints, have not been
shown to be independent prognostic factors [145].
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3.2. Case nr. 2
A 48-year old female diagnosed with seropositive rheumatoid arthritis in 2004. Since 2004
the patient was treated with prednisolone, at the highest dose of 15mg/day. She has also re‐
ceived nonsteroidal anti-inflammatory drugs (NSAIDs) - paracetamol, ibuprofen, naproxen,
diclofenac, recently ketoprofen. Since 2005 she has not taken any disease modifying anti‐
rheumatic drugs (DMARD’s), although methotrexate and sulfasalazine were prescribed. The
patient on her own decided to stop the treatment and did not cooperate with physicians.
In the spring of 2012 patient was admitted to the Department of Systemic Connective Tissue Dis‐
eases in Institute of Rheumatology with big flare-ups. Assessed Disease Activity Score 28 (DAS
28) was 7.22 (22 painful joints, 13 swollen joints, VAS-80, ESR-34mm/h). She has elevated rheu‐
matoid factor - 681IU/ml, highly positive level of anti-citrullinated protein/peptide antibodies
(ACPA) – 263,5U/ml. Physical examination revealed numerous rheumatoid nodules, with di‐
ameter range from 2 to 3 cm. The nodules were located on the extensor parts of the proximal in‐
terphalangeal and metacarpophalangeal joints and around wrists and ankles and elbows. The
radiographs showed advanced changes from rheumatoid arthritis, ankylosis, joints subluxa‐
tions, the highest degree of radiological V, according to Larsen - it means mutilating changes,
where the original bony outlines have been destroyed [143].
In therapy the patient received the reference dose of methotrexate (25mg per week), the
dose of glucocorticosteroids was reduced to 7,5mg/ day, and the dose of ketoprofen was re‐
duced to 100mg per day. Patient was admitted to the Department one month after the start
of the therapy. Disease Activity Score 28 went down to 3,3 (2 painful joints, 1 swollen joint,
VAS- 55.) Inflammatory parameters were reduced ( ESR-8mm/h, CRP- 3 mg/dl).
The purpose of the presentation of this case is to show a patient with aggressive natural
course of disease, advanced articular changes and extra-articular complications - rheuma‐
toid nodules. Rheumatoid nodules are benign structures, that relate to positive rheumatoid
factor in 90%. Although there is no correlation between nodules, rheumatoid arthritis pro‐
gression and severity of this disease, patients with rheumatoid nodules are recommended to
take more aggressive treatment. Rheumatoid nodules are a cosmetic issue and do not re‐
quire treatment, however complications can occur. There is high probability of infection, ul‐
ceration or even gangrene. Sometimes the internal nodules cause fistula. In this case there is
a need for the surgical procedure. When nodules are painful, limit the motion or damage the
underling structures, the injection of corticosteroids can reduce these symptoms. Conven‐
tional treatment (DMARD’s) usually reduce or even completely resolve rheumatoid nod‐
ules. There are however published cases of accelerated rheumatoid nodules, that respond
differently to the conventional treatment. In 1986 Kremer and Lee described the occurrence
of such nodules during a study of a long-term methotrexate therapy [146]. Three patients
had an increasing number of nodules during a therapy of methotrexate. Since then there has
been a lot more descriptions of complications of methotrexate therapy. Usually patients
complain of small, painful nodules on the hands – metacarpophalangeal and proximal inter‐
phalangeal joints, feet and ears. These observations were confirmed by Ahmed and cowork‐
ers. They arranged double blind study with methotrexate and azathioprine with patient
with rheumatoid arthritis. Study showed an 8% incidence of methotrexate–induce accelerat‐
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ed rheumatoid nodules with arthritis improved and none of azathioprine [147]. Combined
therapy- methotrexate and one of the following drugs: hydroxychloroquine [148], D-penicil‐
amine [149], colchicine [150] or sulfasalazine [151] reduce probability of incidence of acceler‐
ated rheumatoid nodules. There are also case reports of another drug which have been
implicated in occurrence of accelerated rheumatoid nodules. Anti-TNF-α therapy with eta‐
nercept can cause appearance of rheumatoid nodules.
 
Figure 2. Case nr.2. A 48-year old female diagnosed with seropositive rheumatoid arthritis. She has numerous rheu‐
matoid nodules.
The case report described above shows a patient with numerous rheumatoid nodules. This
case is not related to the complications of methotrexate therapy, this is a typical case, where
methotrexate decreased the size of nodules. However, there is an example of patient with
very advanced clinical stage of rheumatoid arthritis (anykylosis in the hands during 7 years
natural course of the RA). In the era of disease modifying antirheumatic drugs and biologi‐
cal treatment such case should never have happened. Patients who are quickly diagnosed
with RA, should receive appropriate treatment within three months from the diagnosis.
First step is DMARD’s therapy. After three months of combined therapy (two different
DMARD’s including methotrexate 25mg/week [152]), patients require anti–TNF-α therapy
combined with methotrexate. If this treatment fails, patients with seropositive RA should
undergo an anti CD20 therapy – rituximab [153]. If the patients are seronegative RA, they
should receive another biological agent (inhibitor IL-6, or anti IL-1 or fusion protein bind
CTLA-4) [144]. Only this way patients with RA are able to significantly reduce the chance of
disease progression.
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3.3. Case nr. 3
A 68 year old patient, diagnosed with seropositive rheumatoid arthritis in 1978. In 2007 the pa‐
tient was diagnosed with kidney failure based on the functional parameters of kidney: (creati‐
nine 2.1 mg/dl, urea 150mg/dl, GFR-60) - renal insufficiency, (proteinuria over 3.5 grams/day,
hypoalbuminemia, edema of lower limbs) - nephritic syndrome. Biopsy obtained from adipose
tissue showed amyloidosis associated with RA. The patient has been hospitalized at the Insti‐
tute of Rheumatology since 2008. She was admitted from Nefrology Department with severe
microcytic anemia (Hb-7,6 g/dl, MCV- 83fL) after blood transfusion. She received 4 units of
blood and she was qualified to erytropoietin treatment. She has also big exacerbation of rheuma‐
toid inflammations (ESR- 107mm/h, CRP-86mg/l), Diseases Activity Score 28 (DAS28)- 6,69 ( 9-
swollen joins, 9-painful joins, VAS-64). The patient was diagnosed with secondary Sjogren’s
syndrome based on dry mouth and eyes, positive Schirmer test - keratocjuctivitis sicca and his‐
topathological examination - focus score of 2. The radiographs show advanced changes of rheu‐
matoid arthritis with presence of erosions and joint subluxations -  the highest degree of
radiological V, according to Larsen- it means mutilating changes, where the original bony out‐
lines have been destroyed [143]. She was treated with small doses of glucocorticosteroids and
cyclophosphamid. The patient tolerated well the first 2 grams of cyclophosphamid treatment.
Further therapy went with complications. After the patient fell down on the left shin, she has
had abscess. Staphyloccocus aureus grew in bacteriological sowing. Patient received antibioti‐
cotherapy, cytostatic treatment was stopped. After one month of antibiotic therapy, the Staphy‐
loccocus was still present in the sowing from endoprosthetic knee. She took antibiotics for over
six months. In 2010 the patient received cytostatic treatment one more time. There was no bacte‐
ria present anymore. After administering the second gram of cyclofosfamid there was an in‐
crease of renal insufficiency, therefore the cyclostatic treatment was terminated. Over a 34-year
period of time, the patient received various disease modifying antirheumatic drugs (DMARD’s)
- sulfasalazine, hydroxychloroquinee, cyclosporine, gold salts - with no therapeutic effect. Pa‐
tient does not tolerate methotrexate, azathioprine and cyclophosphamid. Currently patient is
treated with anti-TNF-α monotherapy with good tolerance, low inflammatory parameters and
stabilization of kidney functions.
The description of this case is to show an aggressive course of disease with multiple exacer‐
bations. The patient was treated with different drugs, which were ineffective or had side ef‐
fects and in the end showed multiple organ damage. The most dangerous is renal failure
caused by amyloidosis. In secondary amyloidosis AA renal involvement is observed in ap‐
proximately 90% of all cases. Serum amyloid A (SSA) is responsible for amyloid deposits in
involved organ. Concentration of amyloid A is proportional to inflammations process. Amy‐
loidosis is diagnosed after about 17 years (4-40) of active rheumatoid arthritis [154]. Amy‐
loid deposits concentrate in the renal capsule, particularly in mezangium, in the Bowman’s
capsule, but also in the renal pelvis, perynchema and in renal vessels. 95% of patients with
secondary amyloidosis have proteinuria [155], nephritic syndrome or a different kind of kid‐
ney failure (hematuria, defect of renal pelvis or urinal infections). Main aim of the therapy in
systemic amyloidosis is reducing and eliminating existing protein production or prohibiting
further deposition of amyloid fibrils in organs.
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The easiest way to reduce serum amyloid A is to reduce inflammations process by reducing
CRP level by use DMARD’s therapy [156] or anti -TNF-α therapy [157]. TNF-α inhibitor ach‐
ieved therapeutic success by reducing level of serum IL-6 [158,159]. Low level of serum IL-6
stops the synthesis of acute-phase proteins, systemic inflammation is suppressed, and SAA
levels are lowered by decreasing polimorphism SAA1 gene. This supresses hepatocytes
leading to reduction of amyloid deposits. New alternative is inhibitor IL-6- tociluzumab, a
drug that directly inhibits polimorphism SAA1 gene [160,161].
Another way to stop amyloidosis is to reduce amyloidogenesis by stabilizing amyloid de‐
posits in tissues. This aim can be achieved by interactions between amyloidogenic proteins
and glycosaminoglycans promote fibril. There is a drug – eprodisate - which stops binding
of SAA protein to precursor, next prohibiting polymerization of amyloid fibrils and deposi‐
tion of the fibrils in tissues [162]. In 2007, Dember and coworkers published a multicenter,
randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of
eprodisate in patients with AA amyloidosis and kidney involvement. Eprodisate slow pro‐
gression in the renal, stabilize renal functions and stop progression of amyloid deposits [95].
 
Figure 3. Case nr 3. A 68 year old patient, diagnosed with seropositive rheumatoid arthritis, secondary amylosidosis.
Advanced changes in joins, the highest degree of radiological V, according to Larsen
The patient described above received the appropriate treatment. Rheumatoid arthritis and
secondary amyloidosis required first classic treatment - DMARD’s therapy (first drug in this
case is cyclophosphamid) with glucocorticosteroids, next in case of this treatment’s failure -
anti-TNF-α therapy or inhibitors IL-6.
3.4. Case nr. 4
A 45 year old female was diagnosed with seropositive rheumatoid arthritis in 2000. She was
treated with sulfasalazine, hydroxychlorochine and low dose of prednisolone.
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On the December of 2006 the patient was admitted to the Department of Pulmonology with
dyspnea and chest pain. Pleuritis with pleural effusion and degraded mass in the right lung
were revealed based on chest X-ray. Bronchoscopy with cytology was taken. The result ex‐
cluded bacterial infections and tuberculosis (cultures, PCR). Patient did not consent to pleu‐
ral puncture. Tuberculostatic treatment was induced without influence on described lung
changes. After 6 months pleural puncture was performed aspirating 1100ml of effusion flu‐
id. The fluid had 46% of lymphocyte, very low level of glucose and highly positive rheuma‐
toid factor, suggesting inflammation associated with RA exacerbation. Further
investigations excluded heart failure and lung cancer. CT scan showed pleural effusion and
mass (1,8 centimeters) suggested rheumatoid nodule in the third segment of right lung. The
biopsy confirmed the diagnosis.
Patient was admitted to the Department of Rheumatology. Physical examination showed ex‐
acerbation of RA: 13 swollen joints, 11 painful, VAS - 68, ESR - 15mm/h and DAS28 - 5.8.
Laboratory test revealed positive rheumatoid factor. Radiograms showed third degree in
Larsen Scale (marked erosions in the joint surfaces). Other connective tissue diseases were
excluded. The patient received 40mg/ day of methylprednisolone and methotrexate. The
treatment was ineffective. Although the patient felt better, there were decreased swollen and
painful joins with the same amount of fluid effusion. The treatment was switched to sulfa‐
salzine, hydroxychloroquine and mehotrexate. It turned out that the patient does not toler‐
ate methotrexate. On April of 2008 the patient was started on leflunamid treatment with
good tolerance. The disease activity decreased to medium-low (DAS28 = 3.04). The inflam‐
mation in the lungs stabilized with a tendency to decrease in the amount of fluid in the pleu‐
ral cavity.
This case shows that the image of RA can vary. A patient with rheumatoid arthritis requires
an interdisciplinary care and multi-diagnosis. Therapies should be directed not only toward
the treatment of arthritis, but also treatment of exacerbation of respiratory failure.
Pleural involvement is the most common manifestation of lung disease in rheumatoid ar‐
thritis. The prevalence is estimated to 5-20% patients with rheumatoid arthritis [61]. Other
lung manifestations in rheumatoid arthritis are: rheumatoid nodules, interstitial lung diseas‐
es (heterogeneous group of disease depending of damage to the lung by inflammation or
fibrosis), pulmonary hypertension, methotrexate induced lung diseases.
Traditional treatment of lung involvement in rheumatoid arthritis is corticosteroids. When
there is pleural involvement, the treatment includes drainage of recurrent symptomatic effu‐
sion and oral corticosteroids, and treatment for the underlying rheumatoid arthritis. Next al‐
ternative treatment, especially for lung fibrosis, are cyclophosphamide [163], cyclosporine,
azathioprine [163], and hydroxychloroquine [80]. Some case studies by Antoniou KM et al.
suggest that infliximab may have an effect on interstitial lung diseases associated with rheu‐
matoid arthritis. This study showed that infliximab can lead to stabilization or improvement
of symptoms, lung function and lung image in X-rays [164].
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 Figure 4. Case nr 4. A 45 year old female was diagnosed with seropositive rheumatoid arthritis, and lung involvement.
X-rays showed right pleural effusion and in upper-middle side of right lung there was 1.6 centimetres mass looked like
rheumatoid nodule.
4. Conclusion
Rheumatoid arthritis’ course may vary. The occurrence of extraskeletal manifestations re‐
quires different diagnostic procedures and treatment. Many of extrasceletal manifestations
are associated with more active or aggressive course of RA. Currently there are no predic‐
tors for extrasceletal manifestations which may suggest their presence in course of disease,
although they are associated with risk factors like smoking, age, sex, level if inflammatory
mediators, presence of rheumatoid factor, antinuclear antibodies and genetic factors. Extra‐
skelatal features of RA are common and generally linked with aggressive course of disease.
They need to be recognized early and treated in proper way.
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